|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12.02.25 - 07:33
|
Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board (GlobeNewswire EN)
|
|
|
Dijon, FRANCE, February 12, 2025 – 0730 (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces that, as of February 17, its Executive Board will be made up of Patrick Alexandre, Chairman, and Isabelle Liebschutz, Quality and Regulatory Affairs Director and the Company's qualified person. Their terms of office were renewed by the Supervisory Board at its meeting on 11 February, for a period of 4 years. Olivier Giré's membership of the Executive Board was not renewed in view of his upcoming departure from Crossject, and will expire on February 17, 2025....
|
|
|
06.02.25 - 07:33
|
COMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE ISSUE OF A SECOND ASSIMILABLE TRANCHE (GlobeNewswire EN)
|
|
|
Press ReleaseDijon, FRANCE, February 6, 2025 –0730h (CET) – Crossject (ISIN: FR0011716265; Euronext Growth : ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces, in accordance with the agreement entered into with Heights in December 2024, the completion of the amendments of the terms and conditions of the bonds issued to an entity affiliated to Heights (the "Investor") in February 2024, and the issue to the Investor of a second tranche of a nominal value of €2,496,400 at an issue price representing 90% of the nominal value of the bonds, ie. €2,246,400 (the “Transaction”)....
|
|
|
|
|
11.12.24 - 08:42
|
Crossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M (GlobeNewswire EN)
|
|
|
Dijon, FRANCE, December 11, 2024 – 8 a.m. (CET) – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces the successful pricing of a reserved capital increase (the “Capital Increase”) of EUR 7.2M through the issuance of 3,635,756 shares with a nominal value of EUR 0.10 each (the “New Shares”), representing 8.8% of its current share capital, at a subscription price of EUR 1.6012 per share, and the issuance of 3,635,756 warrants (the “Warrants”) at a price of EUR 0.3788 per Warrant (the “Warrant Issuance” and, together with the Capital Increase, the “Transaction”). Four Warrants give the right to subscribe to five ordinary shares upon payment of an exercise price of EUR 2.25 per ordinary share. The total number of ordinary shares which can be subscribed upon exercise of the 3,635,756 Warrants amounts ...
|
|
|
10.12.24 - 19:18
|
Crossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m (GlobeNewswire EN)
|
|
|
DIJON, FRANCE, December 10, 2024 – 7:15 p.m. (CET) – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, has been in discussions with investors regarding a private placement comprising an issue of new ordinary shares and warrants for a total gross amount of at least EUR 7 million. Crossject (“Crossject” or the “Company”) has engaged Maxim Group LLC to act as lead placement agent and Invest Securities to act as co-placement agent....
|
|
|
09.12.24 - 07:33
|
Crossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement (GlobeNewswire EN)
|
|
|
Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO® autoinjector to deliver life-saving medicines in emergency situations, and the U.S. Department of Defense (DOD), have relaunched their cooperative research on needle-free autoinjectors, signing an extension of their Cooperative Research and Development Agreement (CRADA) from October 2019. As part of the agreement, the DOD will evaluate an upgraded version of the company's proprietary needle-free autoinjector ZENEO®....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
